title: Glucocorticoid receptor stimulation and the regulation of neonatal cerebellar neural progenitor cell apoptosis.
abstract: Glucocorticoids are used to treat respiratory dysfunction associated with premature birth but have been shown to cause neurodevelopmental deficits when used therapeutically. Recently, we established that acute glucocorticoid exposure at clinically relevant doses produces neural progenitor cell apoptosis in the external granule layer of the developing mouse cerebellum and permanent decreases in the number of cerebellar neurons. As the cerebellum naturally matures and neurogenesis is no longer needed, the external granule layer decreases proliferation and permanently disappears during the second week of life. At this same time, corticosterone (the endogenous rodent glucocorticoid) release increases and a glucocorticoid-metabolizing enzyme that protects the external granule layer against glucocorticoid receptor stimulation (11β-Hydroxysteroid-Dehydrogenase-Type 2; HSD2) naturally disappears. Here we show that HSD2 inhibition and raising corticosterone to adult physiological levels both can independently increase neural progenitor cell apoptosis in the neonatal mouse. Conversely, glucocorticoid receptor antagonism decreases natural physiological apoptosis in this same progenitor cell population suggesting that endogenous glucocorticoid stimulation may regulate apoptosis in the external granule layer. We also found that glucocorticoids which HSD2 can effectively metabolize generate less external granule layer apoptosis than glucocorticoids this enzyme is ineffective at breaking down. This finding may explain why glucocorticoids that this enzyme can metabolize are clinically effective at treating respiratory dysfunction yet seem to produce no neurodevelopmental deficits. Finally, we demonstrate that both acute and chronic glucocorticoid exposures produce external granule layer apoptosis but without appropriate control groups this effect becomes masked. These results are discussed in terms of their implications for glucocorticoid therapy and neurodevelopment during the perinatal period.
authors.affiliation: Washington University in Saint Louis, School of Medicine, Department of Psychiatry, 660 South Euclid, Box #8134, Saint Louis, MO 63110, USA. noguchik@psychiatry.wustl.ed
authors.forename: Kevin K
authors.initials: KK
authors.lastname: Noguchi
authors.forename: Karen
authors.initials: K
authors.lastname: Lau
authors.forename: Derek J
authors.initials: DJ
authors.lastname: Smith
authors.forename: Brant S
authors.initials: BS
authors.lastname: Swiney
authors.forename: Nuri B
authors.initials: NB
authors.lastname: Farber
mesh_terms: D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism*; D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000502:physiology*; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002531:Cerebellum / Q000166:cytology / Q000254:growth & development / Q000378:metabolism*; D003345:Corticosterone / Q000096:biosynthesis / Q000502:physiology; D051379:Mice; D008813:Mice, Inbred ICR; D055495:Neurogenesis / Q000187:drug effects / Q000502:physiology; D011965:Receptors, Glucocorticoid / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism*; D013234:Stem Cells / Q000166:cytology / Q000378:metabolism*
chemical_list: D011965:Receptors, Glucocorticoid; D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2; D003345:Corticosterone